Further studies on patients with diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD) explored the link to CKM progression.<h4>Results</h4>A total of 21,026 participants with CKM stages 1 or 2 at baseline. The gene discussed is CKM; the disease is metabolic dysfunction-associated steatotic liver disease.